ArticleAdvances in pharmacological and pharmaceutical sciences2024
Inhibition of Pancreatic Lipase by Flavonoid Derivatives:
Article in Advances in pharmacological and pharmaceutical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- Synergistic lipase inhibition by Garcinia parvifolia metabolites: aMetabolomics : Official journal of the Metabolomic Society · 2026Article
- Experimental Design-Driven Optimization of Choline-Based Natural Deep Eutectic Solvents for the Extraction of Bioactive Compounds fromMolecules (Basel, Switzerland) · 2026Article
- Microbial biotransformation of Syzygium australe modifies metabolomic profile assessed with multivariate analysis and molecular networking: In vitro and computational studies.Scientific reports · 2026Article
- Identification of Potential Pancreatic Lipase Inhibitors from Traditional Chinese Medicines via Molecular Docking, Molecular Dynamics Simulation and In Vitro Validation.Current issues in molecular biology · 2026Article
- Preclinical Evaluation of Anti-Acne Topical Creams Containing Psorospermum Febrifugum Stem Bark Extract: Lipase Inhibition, Sebum Regulation, and Dermal Safety.Clinical, cosmetic and investigational dermatology · 2026Article
- Synthetic pancreatic lipase inhibitors in obesity treatment: current updates onRSC medicinal chemistry · 2025Review
- Flavonols as potent inhibitors of tyrosinase & pancreatic lipase: synthesis, docking, MD simulation, DFT, and ADMET.Future medicinal chemistry · 2025Article
- Piperidines as dual inhibitors of tyrosinase and pancreatic lipase:Future medicinal chemistry · 2025Article
- Combined Potential of Orlistat with Natural Sources and Their Bioactive Compounds Against Obesity: A Review.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity, characterized by excessive adipose tissue accumulation, has emerged as a crucial determinant for a wide range of chronic medical conditions. The identification of effective interventions for obesity is of utmost importance. Widely researched antiobesity agents focus on pancreatic lipase, a significant therapeutic target. This study presented the evaluation of ten flavonoid compounds in terms of their inhibitory activities against pancreatic lipase, utilizing both
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.